Min Fang

Dr. Min Fang

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MFMin Fang
Min Fang
JYJingping Yuan
Jingping Yuan
MCMengyuan Chen
Mengyuan Chen
ZSZongwen Sun
Zongwen Sun
LLLulu Liu
Lulu Liu
MCMing Chen
Ming Chen
The present study was performed to quantify tumor neo-vessels, macrophages and fibroblasts in the tumor microenvironment of hepatocellular carcinoma (HCC) and explore the prognostic factors of HCC. The distribution of tumor neo-vessels, macrophages and fibroblasts was quantified by immunohistochemistry and inverted microscopy with the CRi Nuance multispectral imaging system, and the correlation of these parameters with the clinico‑pathological characteristics and overall survival of the patients was analyzed. The number of tumor neo‑vessels and macrophages, and density of the fibroblasts, as calculated by the thickness of the tumor stroma in the tumor microenvironment, ranged from 51‑429 (median, 218), 110‑555 (median, 259) and 35.6‑555.5 µm (median, 247.0), respectively. Using the median values as a cutoff, the cases were stratified into high‑ and low‑density groups. Survival analysis demonstrated that the high‑density groups regarding macrophages (χ2=5.249, P=0.022) and fibroblasts (χ2=18.073, P<0.001) had a significantly shorter disease‑free survival (DFS) than the low‑density groups. The high‑density tumor neo‑vessel group had a shorter DFS with a median of 5 months than the low‑density group with a median of 7 months; however, there was no statistical significance between these two groups (χ2=1.663, P=0.197). Regarding the above three stromal components combined, all of the cases were classified into low‑, middle‑ and high‑density groups. Survival analysis demonstrated that the high‑density group of stromal components had a shorter DFS than the other two groups with a median of 3 months (χ2=14.439, P=0.001). Multivariate analysis by Cox regression indicated that cirrhosis, metastasis stage, as well as macrophage and fibroblast density were independent prognostic factors. In conclusion, the key elements in the tumor microenvironment, including tumor neo‑vessels, macrophages and fibroblasts, were heterogenic in HCC tissues and have significant roles in HCC invasion and metastasis. Stromal components are associated with the prognosis of patients with HCC; the higher the density of stromal components, the poorer the prognosis of patients with HCC.

16 August 2023 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
MFMin Fang
Min Fang
LWLe Wang
Le Wang
QGQing Gu
Qing Gu
HWHuiwen Wu
Huiwen Wu
XDXianghui Du
Xianghui Du
XLXiaojing Lai
Xiaojing Lai

14 February 2023 in Oncology Letters
Verified
Journal Article
Open access
PDF file
HYHangjie Ying
Hangjie Ying
QHQingqing Hang
Qingqing Hang
GCGuoping Cheng
Guoping Cheng
SYShifeng Yang
Shifeng Yang
XLXiaojing Lai
Xiaojing Lai
MFMin Fang
Min Fang
The present study aimed to clarify the association between macrophages, tumor neo‑vessels and programmed cell death‑ligand 1 (PD‑L1) in the tumor microenvironment and the clinicopathological features of patients with non‑small cell lung cancer (NSCLC), and to explore the prognostic factors of stromal features in NSCLC. To determine this, tissue microarrays containing samples of 92 patients with NSCLC were studied using immunohistochemistry and immunofluorescence. The quantitative data demonstrated that in tumor islets, the number of CD68+ and CD206+ tumor‑associated macrophages (TAMs) was 8‑348 (median, 131) and 2‑220 (median, 52), respectively (P<0.001). In tumor stroma, the number of CD68+ and CD206+ TAMs was 23‑412 (median, 169) and 7‑358 (median, 81), respectively (P<0.001). The number of CD68+ TAMs in each location of the tumor islets and tumor stroma was significantly higher than that of CD206+ TAMs, and they were significantly correlated (P<0.0001). The quantitative density of CD105 and PD‑L1 in tumor tissues was 19‑368 (median, 156) and 9‑493 (median, 103), respectively. Survival analysis revealed that a high density of CD68+ TAMs in tumor stroma and islets and a high density of CD206+ TAMs and PD‑L1 in tumor stroma were associated with worse prognosis (both P<0.05). Collectively, the survival analysis demonstrated that the high‑density group was related to a worse prognosis regardless of combined neo‑vessels and PD‑L1 expression with the CD68+ TAMs in tumor islets and stroma, or CD206+ TAMs in tumor islets and stroma. To the best of our knowledge, the present study was the first to provide a multi‑component combined prognostic survival analysis of different types of macrophages in different regions with tumor neo‑vessels and PD‑L1, which demonstrated the importance of macrophages in tumor stroma.

9 May 2023 in Research Square
Verified
Preprint
Open access
PDF file
MFMin Fang
Min Fang
LWLe Wang
Le Wang
QGQing Gu
Qing Gu
HWHuiwen Wu
Huiwen Wu
XDXianghui Du
Xianghui Du
XLXiaojing Lai
Xiaojing Lai
Purpose The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. This study was aimed to evaluate the efficacy and safety of TRT for ES-SCLC after first line chemoimmunotherapy.Methods ES-SCLC patients who received immunotherapy in Zhejiang Cancer Hospital has been retrospectively analyzed between January 2020 and November 2021. Patients were assigned to receive either TRT or no TRT. Oligo-metastatic disease was defined as 3 or less discrete distant metastases with no more than 2 organs. Propensity score matching (PSM) was performed in two groups. The main outcome measures were progression-free survival (PFS), local recurrence-free survival (LRFS) and OS.Results 111 patients with ES-SCLC were enrolled in this study, the median OS was 14 months. 39 patients received TRT after chemoimmunotherapy (TRT group) and 72 patients did not receive TRT (no TRT group). TRT group improved OS (HR 0.58, 95% CI 0.34–0.99, p = 0.0445), PFS (HR 0.59, 95% CI 0.38–0.90, p = 0.0149) and LRFS (HR 0.3, 95% CI 0.16–0.56, p = 0.0001). Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis. This trend persisted after PSM. However, OS in oligo-metastasis and non-liver metastasis subgroup was without significant difference.Conclusion TRT improved LRFS, PFS and OS for ES-SCLC with thoracic residual after chemoimmunotherapy with well tolerated toxicity.